DexCom Operating Cycle from 2010 to 2026

DXCM Stock  USD 73.04  0.00  0.00%   
DexCom Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 119.68. During the period from 2010 to 2026, DexCom Operating Cycle quarterly data regression pattern had sample variance of  2,588 and median of  150.39. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
195.96
Current Value
119.68
Quarterly Volatility
50.8709208
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.2 M, Other Operating Expenses of 4.1 B or Operating Income of 724.5 M, as well as many indicators such as Price To Sales Ratio of 8.52, Dividend Yield of 0.0 or PTB Ratio of 10.1. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
Build AI portfolio with DexCom Stock
Check out the analysis of DexCom Correlation against competitors.
Evaluating DexCom's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.

Latest DexCom's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of DexCom Inc over the last few years. It is DexCom's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

DexCom Operating Cycle Regression Statistics

Arithmetic Mean163.58
Geometric Mean155.69
Coefficient Of Variation31.10
Mean Deviation41.93
Median150.39
Standard Deviation50.87
Sample Variance2,588
Range185
R-Value0.68
Mean Square Error1,498
R-Squared0.46
Significance0
Slope6.81
Total Sum of Squares41,406

DexCom Operating Cycle History

2026 119.68
2025 195.96
2024 217.73
2023 252.69
2022 203.39
2021 246.82
2020 213.66

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as Operating Cycle, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 195.96  119.68 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.099
Earnings Share
1.8
Revenue Per Share
11.544
Quarterly Revenue Growth
0.216
Return On Assets
0.0702
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value—what DexCom's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.